Ingevity (NGVT) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month price targets for Ingevity's stock. Their NGVT share price forecasts range from $55.00 to $75.00. On average, they expect the company's stock price to reach $63.33 in the next year. This suggests a possible upside of 36.5% from the stock's current price.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $70.44 on January 1st, 2023. Since then, NGVT shares have decreased by 34.1% and is now trading at $46.40.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported $1.41 earnings per share for the quarter, hitting analysts' consensus estimates of $1.41. The firm earned $481.80 million during the quarter, compared to the consensus estimate of $486.43 million. Ingevity had a trailing twelve-month return on equity of 27.94% and a net margin of 10.18%. The company's quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.73 EPS.

ETFs with the largest weight of Ingevity (NYSE:NGVT) stock in their portfolio include Invesco S&P SmallCap Materials ETF (PSCM), ProShares Smart Materials ETF (TINT), Putnam BioRevolution ETF (SYNB) and Thrivent Small-Mid Cap ESG ETF (TSME).Avantis U.S. Small Cap Equity ETF (AVSC).

Ingevity updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.60 billion-$1.70 billion, compared to the consensus revenue estimate of $1.82 billion.

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NGVT stock can currently be purchased for approximately $46.40.

Ingevity (NYSE:NGVT) has a market capitalization of $1.68 billion and generates $1.67 billion in revenue each year. The company earns $211.60 million in net income (profit) each year or $4.71 on an earnings per share basis.

The company employs 2,050 workers across the globe.

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for the company is www.ingevity.com. The company can be reached via phone at (843) 740-2300, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.